--- title: "Windward Bio climbs 5% on $175 million IPO pricing" type: "News" locale: "en" url: "https://longbridge.com/en/news/305707229.md" description: "Windward Bio rose 4.91% to $29.90 after pricing its IPO to raise $175 million plus a $50 million Sanofi private placement." datetime: "2026-11-16T19:10:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/305707229.md) - [en](https://longbridge.com/en/news/305707229.md) - [zh-HK](https://longbridge.com/zh-HK/news/305707229.md) generator: "portal-rs" --- # Windward Bio climbs 5% on $175 million IPO pricing Windward Bio Group (WWB.US) climbed nearly **5%** during regular trading to **$29.90**. The company priced its Nasdaq initial public offering to raise **$175 million**, excluding the over-allotment option, and simultaneously secured a **$50 million** private placement with Sanofi, bringing total expected proceeds to **$225 million**. Windward Bio listed on the Nasdaq on Nov. 13, 2026, at an IPO price of **$17** per share. The company focuses on developing ultra-long-acting antibodies for respiratory and dermatological diseases. Its lead candidate, WIN378, has shown positive interim results in asthma and is set to begin a Phase III clinical trial in September 2026. Based on public media reports. AI-generated; not investment advice. ### Related Stocks - [WWB.US](https://longbridge.com/en/quote/WWB.US.md) ## Related News & Research - [Windward Bio prices $175 million Nasdaq IPO](https://longbridge.com/en/news/305634890.md) - [Windward Bio Group: WIN378 advances in asthma as ultra-long-acting programs target twice-yearly dosing](https://longbridge.com/en/news/305951590.md) - [Windward Bio Raises $50 Million in Private Placement to Sanofi Foreign Participations](https://longbridge.com/en/news/305719353.md) - [Novo Holdings-backed Windward Bio valued at $1 billion as shares rise in Nasdaq debut](https://longbridge.com/en/news/305492826.md) - [Windward Bio Presents at Jefferies Global Healthcare Conference](https://longbridge.com/en/news/305870877.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**